Literature DB >> 2865156

Cold sensitivity in essential hypertension: the effect of beta- and combined alpha- and beta-blockade.

E D Cooke, S A Bowcock, A T Smith.   

Abstract

The presence of cold sensitivity was investigated in three groups of patients; untreated hypertensives and hypertensives treated by a beta-adrenoceptor blocker (propranolol) or by a combined alpha- and beta-adrenoceptor blocker (labetalol) at two ambient temperatures. At a comfortable ambient (24 degrees C) one-third of the untreated and those treated with beta-blockade only showed cold sensitivity as compared with 16% of patients on the combined therapy. Under conditions of mild cold stress (20 degrees C) cold sensitivity increased in frequency in all three groups, more than half of the untreated and beta-blocked patients were affected and greater than one-third of those with alpha- and beta-blockade. These findings indicate that in the general population of hypertensives treatment with beta-adrenoceptor blockade alone may have little effect on the peripheral vasculature and that a useful degree of protection may be provided by therapy which blocks both receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865156     DOI: 10.1007/bf00547365

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  A vascular abnormality in hypertension. A study of blood flow in the forearm.

Authors:  J CONWAY
Journal:  Circulation       Date:  1963-04       Impact factor: 29.690

2.  Peripheral skin necrosis complicating beta-blockage.

Authors:  R Gokal; T L Dornan; J G Ledingham
Journal:  Br Med J       Date:  1979-03-17

3.  Preliminary studies of the pharmacological effects of 5-[1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)-ethyl] salicylamide (AH 5158) in man.

Authors:  A J Boakes; E J Knight; B N Prichard
Journal:  Clin Sci       Date:  1971-04       Impact factor: 6.124

4.  Propranolol in hypertension: a study of long-term therapy, 1964-1970.

Authors:  F J Zacharias; K J Cowen; J Prestt; J Vickers; B G Wall
Journal:  Am Heart J       Date:  1972-06       Impact factor: 4.749

5.  A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome.

Authors:  M H Rustin; S M Grimes; I B Kovacs; E D Cooke; S A Bowcock; S O Sowemimo-Coker; P Turner; J D Kirby
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Alternative mechanisms for the hypotensive effects of adrenergic blockade.

Authors:  I A Greer; J J Walker; M McLaren; J J Belch; A A Calder; C D Forbes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-19

7.  A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.

Authors:  J J McNeil; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

8.  Comparison of labetalol and propranolol in hypertension.

Authors:  D P Nicholls; M H Husaini; C J Bulpitt; M D Stephens; A G Butler
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

9.  Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent.

Authors:  A M Joekes; F D Thompson
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

10.  Effects of combined alpha- and beta-receptor blockade on peripheral circulation in essential hypertension.

Authors:  I Heck; G Trübestein; K O Stumpe
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

View more
  2 in total

Review 1.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

2.  Peripheral vascular effects of beta-adrenoceptor blockade: comparison of two agents.

Authors:  E D Cooke; M B Maltz; R E Smith; S A Bowcock; C J Watkins; A J Camm
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.